Skip to content
Screener

Cytokinetics CYTK Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$66.8MBeat by $64.7M
EPS-$1.12Beat by $0.22
Revenue estimate$2.1M
EPS estimate-$1.34

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$39.9M
EPS estimate-$1.45

Financials

Q2 2025

Income statement

See full
Revenue$66.8M+26,715%
Operating income-$111.5M+14.3%
Net income-$134.4M+6.2%
EPS (diluted)-$1.12+14.5%

Balance sheet

See full
Cash & equivalents$74.9M-60.6%
Total debt$304.1M+26.9%
Total equity-$368.7M-440%
Total assets$1.2B-19.6%

Cash flow

See full
Operating cash flow-$128.2M-29.1%
CapEx$4.1M+116%
Free cash flow-$132.4M-30.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$3.99B-37.2%
Enterprise value$4.22B-34.1%
P/S46.5×-1,979×

Profitability

See full
Operating margin-638%-313pp
Net margin-707.2%-346pp
FCF margin-511.7%-251pp

Returns & leverage

See full
Current ratio6.8×-3.6×

Segments

By product

See full
License And Milestone Revenues$64.4M—
Collaboration Revenues$2.4M+870%

FAQ

When did Cytokinetics report Q2 2025 earnings?
Cytokinetics (CYTK) reported Q2 2025 earnings on August 7, 2025 after market close.
What were Cytokinetics's Q2 2025 revenue and EPS?
Cytokinetics reported revenue of $66.8M and eps of $-1.12 for Q2 2025.
Did Cytokinetics beat estimates in Q2 2025?
Revenue beat the consensus estimate of $2.1M by $64.7M. EPS beat the consensus estimate of $-1.34 by $0.22.
How did Cytokinetics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 26714.9% from $249.0K a year earlier and eps grew 14.5% from $-1.31.
Where can I find Cytokinetics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-104962) and the 10-Q periodic report (0000950170-25-105108) directly on SEC EDGAR. The filing index links above go to sec.gov.